When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
KPTI - Karyopharm up 6% on late-stage selinexor data in multiple myeloma
Karyopharm Therapeutics Inc.
Karyopharm Therapeutics (NASDAQ:KPTI) announces detailed results from a Phase 3 clinical trial, BOSTON, evaluating Xpovio (selinexor), combined with Takeda's Velcade (bortezomib) and low-dose dexamethasone, in multiple myeloma patients who had received one-to-three prior lines of therapy. The data will be virtually presented tomorrow at the ASCO Scientific Program.
More news on: Karyopharm Therapeutics Inc., Healthcare stocks news, Stocks on the move,